AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Worlddrugtracker, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India, in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA as ADVISOR earlier GLENMARK LS Research centre as consultant,Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now sSanofi, Searle India ltd, now Rpg lifesciences, etc. he is now helping millions, has million hits on google on all organic chemistry websites. His New Drug Approvals, Green Chemistry International, Eurekamoments in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He gas good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, polymorphism etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, [email protected]

 Permalink  Uncategorized  Comments Off on
May 282013
 

Rituximab (trade names Rituxan and MabThera) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab destroys B cells, and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Rituxan

Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential
Forbes
One small biopharmaceutical that believes it has a proven technology for another blockbuster is TG Therapeutics (TGTX), which is focused on developing drugs for the treatment of cancer and other underserved therapeutic needs, including hematologic …read all

http://www.forbes.com/sites/genemarcial/2013/05/27/tiny-biotech-developing-drugs-akin-to-biogens-rituxan-seen-as-potential-buyout-bet/

Share

Basilea reports isavuconazole orphan drug designation by US FDA

 orphan status  Comments Off on Basilea reports isavuconazole orphan drug designation by US FDA
May 282013
 

isavuconazonium as sulfate

Isavuconazole (BAL4815) is a triazole antifungal. Its prodrug, Isavuconazonium sulfate (BAL8557) is currently in Phase III clinical trials.

Basilea reports isavuconazole orphan drug designation by US FDA
ITNews
Pharmaceutica AG / Basilea reports isavuconazole orphan drug designation by U.S. FDA .

Basel, Switzerland, May 28, 2013 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of invasive aspergillosis. An FDA orphan drug designation provides several benefits to the sponsor including a seven-year market exclusivity from product approval in the U.S. Isavuconazole was previously granted FDA fast track status that is designed to facilitate development and expedite the review of drugs to treat serious diseases

Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational intravenous and oral broad-spectrum antifungal.

In collaboration with Astellas Pharma Inc., isavuconazole is being investigated in phase 3 clinical …  read all at

http://www.itnews.it/news/2013/0528071501820/basilea-reports-isavuconazole-orphan-drug-designation-by-u-s-fda.html

Share

CFDA Approves Clinical Trials for Novel China AIDS Treatment, Azi Fu (Azvudine)

 AIDS, Uncategorized  Comments Off on CFDA Approves Clinical Trials for Novel China AIDS Treatment, Azi Fu (Azvudine)
May 282013
 

Links

http://newdrugapprovals.wordpress.com/2013/05/28/cfda-approves-clinical-trials-for-novel-china-aids-treatment-azi-fu-azvudine/

Share

Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).

 phase 2  Comments Off on Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).
May 282013
 

Links

http://newdrugapprovals.wordpress.com/2013/05/28/swedish-pharmaceutical-company-moberg-pharma-has-completed-enrolling-patients-in-the-ongoing-phase-ii-trial-of-mob-015-for-the-treatment-of-nail-fungus-onychomycosis/

Share

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

 phase 2  Comments Off on Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.
May 282013
 

Links

http://newdrugapprovals.wordpress.com/2013/05/28/sonepcizumablt1009-us-based-lpath-has-begun-patient-dosing-in-phase-2a-single-arm-trial-of-anti-cancer-drug-asonep/

Share

Xarelto approved for Secondary prevention in Acute Coronary Syndrome patients in Europe

 china  Comments Off on Xarelto approved for Secondary prevention in Acute Coronary Syndrome patients in Europe
May 272013
 

 

 

shark

read all

Links

http://newdrugapprovals.wordpress.com/2013/05/27/xarelto-approved-for-secondary-prevention-in-acute-coronary-syndrome-patients-in-europe/

Share

China’s Curative Medical to Seek CFDA Approval for ALung’s Respiratory Device

 china, Uncategorized  Comments Off on China’s Curative Medical to Seek CFDA Approval for ALung’s Respiratory Device
May 272013
 

 

Links

read all at

http://newdrugapprovals.wordpress.com/2013/05/27/chinas-curative-medical-to-seek-cfda-approval-for-alungs-respiratory-device/

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: